Built on our proprietary ImmTAX platform, we have a diverse pipeline of bispecific therapies across a broad range of indications.
Our pipeline includes clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects
Tebentafusp
/ Target: gp100 (A02)Adjuvant uveal (ocular)
melanoma
ATOM sponsored by EORTC
IND-enabling
Phase 1
Phase 2
Phase 3
Phase 3 Start | 2H 2024
2L+ advanced cutaneous melanoma
TEBE-AM
IND-enabling
Phase 1
Phase 2
Phase 3
Phase 3 enrollment completion | 1H 2026
Brenetafusp (IMC-F106C)
/ Target: PRAME (A02)1L advanced cutaneous melanoma
PRISM-MEL-301
IND-enabling
Phase 1
Phase 2
Phase 3
Phase 3 ongoing
Phase 1/2 Monotherapy & Combinations
Cutaneous melanoma
IND-enabling
Phase 1
Phase 2
Phase 3
2L+ Phase 1 Data | ASCO 2024
Ovarian1
IND-enabling
Phase 1
Phase 2
Phase 3
PRR<sup>1</sup> Phase 1 Data | ESMO 2024
NSCLC2
IND-enabling
Phase 1
Phase 2
Phase 3
2L+ Phase 1 Data | 4Q 2024
Advanced endometrial
IND-enabling
Phase 1
Phase 2
Phase 3
Additional solid tumors
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-P115C
/ Target: PRAME-HLE (A02)Multiple solid tumors
IND-enabling
Phase 1
Phase 2
Phase 3
Phase 1 Start | 1H 2025
IMC-T119C
/ Target: PRAME (A24)Multiple solid tumors
IND-enabling
Phase 1
Phase 2
Phase 3
IND/CTA | 4Q 2024
IMC-R117C
/ Target: PIWIL1 (A02)Colorectal and GI cancers
IND-enabling
Phase 1
Phase 2
Phase 3
Phase 1 Start | 2H 2024
IMC-M113V<sup>3</sup>
/ Target: Gag (A02)Human Immunodeficiency Virus (HIV)
IND-enabling
Phase 1
Phase 2
Phase 3
MAD Data | 1Q 2025
IMC-I109V
/ Target: Envelope (A02)Hepatitis B Virus (HBV)
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-S118AI
/ Target: PPI (A02)Type 1 Diabetes
IND-enabling
Phase 1
Phase 2
Phase 3
Undisclosed
/ Target: (universal)<sup>4</sup>Dermatology
IND-enabling
Phase 1
Phase 2
Phase 3
Date last updated: August 8, 2024
1 Platinum refractory or resistant serous ovarian carcinoma. 2 NSCLC = Non-small cell lung cancer. 3 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. 4 Program is not HLA restricted (i.e. universal for all populations)
Disclaimer
All trademarks, company and product names or logos are the property of their respective owners. The efficacy and safety of the molecules under investigation have not yet been established. There is no guarantee that pipeline molecules will receive approval and become commercially available for the uses being investigated as drug development is uncertain and agents in development may be terminated along the development process. The above information is accurate as of September 2024.